SCHEMBL5474329

SCHEMBL5474329

O=C(Nc1ccc2c(c1)OCO2)c1c[c]cc(O)c1O

nearest known ligand 0.57

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ RAB9A P51151 13/20 0.57
▸ NPC1 O15118 12/20 0.57
▸ SMN1; SMN2 Q16637 11/20 0.57
▸ MAPT P10636 9/20 0.57
▸ NFKB1 P19838 4/20 0.57
▸ NFKB2 Q00653 4/20 0.57
▸ RELA Q04206 4/20 0.57
▸ PKM P14618 3/20 0.57
▸ ALDH1A1 P00352 2/20 0.57
▸ TP53 P04637 5/20 0.56
▸ HPGD P15428 2/20 0.56
▸ MEN1 O00255 7/20 0.55
▸ KMT2A Q03164 7/20 0.55
▸ POLB P06746 3/20 0.55
▸ HTT P42858 1/20 0.53
▸ TSHR P16473 1/20 0.53
▸ AHR P35869 1/20 0.52
▸ ALOX15 P16050 1/20 0.52
▸ MAPK1 P28482 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5468828 0.85 NPC1 (0.57) RAB9ANPC1SMN1; SMN2MAPTNFKB1
SCHEMBL14363418 0.80 NPC1 (0.63) RAB9ANPC1SMN1; SMN2MAPTNFKB1
SCHEMBL13189702 0.75 NPC1 (0.70) RAB9ANPC1SMN1; SMN2MAPTNFKB1
SCHEMBL14363317 0.75 NPC1 (0.67) RAB9ANPC1SMN1; SMN2MAPTNFKB1
SCHEMBL27179668 0.74 RAB9A (0.90) RAB9ANPC1SMN1; SMN2MAPTNFKB1
SCHEMBL12700201 0.74 NPC1 (0.75) RAB9ANPC1SMN1; SMN2MAPTNFKB1
SCHEMBL3455487 0.74 RAB9A (0.85) RAB9ANPC1SMN1; SMN2MAPTNFKB1
SCHEMBL108116 0.73 NPC1 (1.00) RAB9ANPC1SMN1; SMN2MAPTNFKB1
SCHEMBL22113950 0.73 NPC1 (0.78) RAB9ANPC1SMN1; SMN2MAPTNFKB1
SCHEMBL4486236 0.72 RAB9A (0.80) RAB9ANPC1SMN1; SMN2MAPTNFKB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070276011-A1 Plasminogen Activator Inhibitor-1 Inhibitor INSTITUTE OF MEDICINAL MOLECULAR DESIGN. INC. (JP) 2007-11-29 — — US disclosed
EP-1666469-A1 PLASMINOGEN ACTIVATOR INHIBITOR-1 INHIBITOR Institute of Medicinal Molecular Design, Inc. (JP) 2006-06-07 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070276011-A1 Plasminogen Activator Inhibitor-1 Inhibitor SERPINE1, SERPINC1, SERPINB1 RAB9A 3765/4885NPC1 3368/4885SMN1; SMN2 2862/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback